Popescu I, Ionescu M, Alexandrescu S, Ciurea S, Hrehoreţ Doina, Sârbu-Boeţi Patricia, Boroş Mirela, Croitoru Adina, Anghel Rodica
Centrul de Chirurgie Generala şi Transplant Hepatic Institul Clinic Fundeni, Bucureşti.
Chirurgia (Bucur). 2006 Jan-Feb;101(1):13-24.
We analyze our experience over a 10-year period in the surgical treatment of liver metastases from colorectal cancer. Between 01.01.1995 and 08.31.2005 189 liver resections were performed in 171 patients with liver metastases from colorectal cancer (16 re-resections - 2 in the same patient and a "two-stage" liver resection in 2 patients). In our series there were 83 patients with synchronous liver metastases (69 simultaneous resections, 12 delayed resections and 2 "two-stage" liver resection were performed) and 88 metachronous liver metastases. Almost all types of liver resections have been performed. The morbidity and mortality rates were 17.4% and 4.7%, respectively. Median survival was 28.5 months and actuarial survival at 1-, 3- and 5-year was 78.7%, 40.4% and 32.7%, respectively. Between January 2002 and August 2005 hyperthermic ablation of colorectal cancer liver metastases has been performed in 6 patients; in other 5 patients with multiple bilobar liver metastases liver resection was associated with radiofrequency ablation and one patient underwent only radiofrequency ablation for recurrent liver metastasis. In conclusion, although the treatment of colorectal cancer liver metastases is multimodal (resection, ablation, chemotherapy and radiation therapy), liver resection is the only potential curative treatment. The quality and volume of remnant liver parenchyma is the only limitation of liver resection. The morbidity, mortality and survival rates after simultaneous liver and colorectal resection are similar with those achieved by delayed resection. Postoperative outcome of patients with major hepatic resection is correlated with the surgical team experience. The long-term survival was increased using the new multimodal treatment schemes.
我们分析了10年间结直肠癌肝转移外科治疗的经验。在1995年1月1日至2005年8月31日期间,对171例结直肠癌肝转移患者实施了189例肝脏切除术(16例再次手术——2例为同一患者再次手术,2例患者进行了“两阶段”肝脏切除术)。在我们的系列研究中,有83例患者为同时性肝转移(实施了69例同期切除术、12例延迟切除术和2例“两阶段”肝脏切除术)以及88例异时性肝转移。几乎实施了所有类型的肝脏切除术。发病率和死亡率分别为17.4%和4.7%。中位生存期为28.5个月,1年、3年和5年的精算生存率分别为78.7%、40.4%和32.7%。2002年1月至2005年8月期间,对6例结直肠癌肝转移患者实施了热消融治疗;另外5例多叶肝转移患者接受了肝脏切除联合射频消融治疗,1例复发性肝转移患者仅接受了射频消融治疗。总之,尽管结直肠癌肝转移的治疗是多模式的(切除、消融、化疗和放疗),但肝脏切除是唯一可能治愈的治疗方法。残余肝实质的质量和体积是肝脏切除的唯一限制因素。同期肝脏和结直肠切除术后的发病率、死亡率和生存率与延迟切除相似。肝大部切除患者的术后结局与手术团队经验相关。采用新的多模式治疗方案可提高长期生存率。